WS
PVLA

Wedbush Securities’s Palvella Therapeutics PVLA Stock Holding History

Wedbush Securities’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-183
Closed -$30K – 992
2020
Q3 		$30K Buy
+183
New +$41.7K ﹤0.01% 910

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedbush Securities's PVLA Position: Q4 2020 in Review

Wedbush Securities sold out of Palvella Therapeutics (PVLA) in Q4 2020, closing a stake of 183 shares — an estimated $30K sold.

Wedbush Securities first reported a position in PVLA in Q3 2020 and held it in 1 quarter. The position peaked at $30K in Q3 2020. 82 funds tracked by Wall St. Rank hold PVLA as of Q4 2020.

  • Wedbush Securities reported no remaining Palvella Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 183 Palvella Therapeutics shares in Q4 2020, an estimated $30K.
  • Wedbush Securities first reported a position in Palvella Therapeutics in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Palvella Therapeutics position peaked at $30K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.